


 Cite this: *Chem. Commun.*, 2024, 60, 4238

 Received 22nd January 2024,
 Accepted 18th March 2024

DOI: 10.1039/d4cc00293h

rsc.li/chemcomm

An organometallic swap strategy for bottlebrush polymer–protein conjugate synthesis†

 Bin Liu,^{ab} Jacob Rodriguez,^{ab} Landon J. Kilgallon,^a Wencong Wang,^a Yuyan Wang,^a Aiden Wang,^a Yutong Dai,^a Hung V.-T. Nguyen,^a Bradley L. Pentelute^{abc} and Jeremiah A. Johnson^{*abc}

Polymer–protein bioconjugation offers a powerful strategy to alter the physical properties of proteins, and various synthetic polymer compositions and architectures have been investigated for this purpose. Nevertheless, conjugation of molecular bottlebrush polymers (BPs) to proteins remains an unsolved challenge due to the large size of BPs and a general lack of methods to transform the chain ends of BPs into functional groups suitable for bioconjugation. Here, we present a strategy to address this challenge in the context of BPs prepared by “graft-through” ring-opening metathesis polymerization (ROMP), one of the most powerful methods for BP synthesis. Quenching ROMP of PEGylated norbornene macromonomers with an activated enyne terminator facilitates the transformation of the BP Ru alkylidene chain ends into Pd oxidative addition complexes (OACs) for facile bioconjugation. This strategy is shown to be effective for the synthesis of two BP–protein conjugates (albumin and ERG), setting the stage for a new class of BP–protein conjugates for future therapeutic and imaging applications.

Protein-polymer conjugates have garnered significant interest due to their applications in materials science and medicine.¹ While a wide range of polymers have been utilized for protein conjugation,¹ polyethylene glycol (PEG) is the most extensively studied and translationally successful, with over 25 “PEGylated” proteins approved by the United States Food and Drug Administration (FDA) to date.² PEGylation can improve the biophysical properties of proteins in several ways.³ For example, the increased size of PEGylated proteins can reduce their renal clearance rate and, as a consequence, increase their circulation half-life.^{2c–g,3} Additionally, PEGylation can protect proteins from

rapid degradation, improve their solubility, and augment their bioavailability and therapeutic efficacy.

Most PEGylated proteins rely on linear PEG macromolecules (Fig. 1a), where features such as molecular weight, number of conjugated PEG chains per protein, and PEG conformation are key variables that impact the biological performance of the resulting conjugates.^{2c,fg,3} “Branched” PEGs have also been explored for protein conjugation, where features such as number of branches and branch length can be used to further vary the PEG conformation and physical properties of the resulting conjugates (Fig. 1a).⁴ For example, Chilkoti and others have utilized polyacrylates with oligoethylene glycol sidechains (~8–9 ethylene glycol repeat units) for protein conjugation (Fig. 1a). These constructs display many of the desirable properties of linear PEGylated proteins while showing reduced immunogenicity in preclinical studies.⁵

These results, along with observations of reduced anti-PEG antibody binding to densely-grafted PEGylated surfaces,




Fig. 1 (a) Previous designs of PEGylated proteins with linear, branched, or brush-like architectures. The red dots represent reactive moieties on the polymers used for conjugation. (b) This work introduces molecular bottlebrush polymer (BP)–protein conjugates prepared through a BP chain-end organometallic swap strategy.

^a Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA. E-mail: jaj2109@mit.edu

^b Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA

^c Broad Institute of MIT and Harvard, Massachusetts Institute of Technology Cambridge, MA, 02142, USA

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4cc00293h>



suggest that PEGylated molecular bottlebrush polymers (BPs), which feature long PEG side chains bound to a rigid polymer backbone, could be advantageous architectures for protein conjugates. To date, however, such conjugates have not been widely reported, presumably due to synthetic challenges associated with the coupling of large molecules (*e.g.*, proteins and BPs) and incompatibility between the common methods for BP synthesis and bioconjugation. Indeed, PEGylated BPs are perhaps most easily synthesized by “graft-through” ring-opening metathesis polymerization (ROMP), wherein a metal-alkylidene chain end (often Ru-based) reacts with strained olefin macromonomers to propagate chain growth.⁶ While highly efficient, such metathesis reactions are generally not commensurate with endogenous protein functionality such as amino and thiol amino acid sidechains,⁷ and efficient methods for conversion of Ru chain ends of BPs to functional groups capable of bioconjugation are not currently available.

Recently, Buchwald, Pentelute, and coworkers pioneered the development of Pd(II) oxidative addition complexes (OACs) as exceptionally efficient reagents for bioconjugation using native cysteine residues of peptides and proteins.⁸ This method features larger second-order rate constants than most other bio-conjugation reactions, making it particularly suitable for intermolecular coupling of large macromolecules, including protein–protein conjugation. Thus, given that the hydrodynamic sizes of PEGylated BPs prepared by ROMP are similar to those of many proteins (~5–15 nm), we hypothesized that the challenge of BP–protein conjugation could be solved by the

development of a method to quantitatively convert the Ru chain ends of BPs to Pd(II) OACs (Fig. 1b).

Here, we report the realization of this concept. First, we show that it is possible to terminate graft-through ROMP of PEG-based MMs with an enyne derivative featuring a Boc-protected primary amine. Boc-removal and coupling with a Pd(II) OAC containing an *N*-hydroxysuccinimidyl ester (NHS) provides BP-OACs capable of direct conjugation to cysteine residues of proteins, using bovine serum albumin (BSA) as a model. Conjugation is confirmed by gel electrophoresis and Förster resonance energy transfer (FRET) experiments, while the stability of the aryl thioether linkage is demonstrated by comparison to an analogous maleimide conjugate. Finally, the generality of the method is demonstrated using a second protein—ERG.

Gutekunst and coworkers have shown that enyne derivatives are outstanding terminators for ROMP, yielding linear polymers with nearly complete chain end modification.⁹ Here, we sought to investigate if such terminators could be used in the context of BPs, which present larger steric limitations, and if they could enable subsequent polymer end-group modification for bioconjugation. Thus, we designed compound **1**, which contains an enyne for ROMP termination, a Boc-protected amine for further functionalization, and a PEG linker to provide space between the BP backbone and the Boc-amine. **1** (Fig. 2a) was synthesized in 47% overall yield on the 50 mg scale from a previously reported secondary amine^{9b} *via* ring-opening of glutaric anhydride and subsequent amidation using a commercially available heterobifunctional PEG containing primary amine and




Fig. 2 Synthesis of BP-BSA conjugates. (a) Scheme for the synthesis of Pd OAC end-functionalized BPs and BP-BSA. (b) SEC traces of PEG-MM and BPs prior to BSA conjugation. (c) ¹H NMR spectrum of BP-NHBoc showing end group fidelity following quenching with enyne **1**.



Boc-protected amine ends (see ESI† for details). PEGylated BPs terminated by **1** (“**BP-NHBoc**”) were synthesized by ROMP as follows: 3 kDa PEG-based MM (PEG-MM, 20 equiv.) was exposed to Grubbs 3rd-generation bis-pyridyl complex (G3, 1 equiv.) at room temperature (RT) for 30 min in THF solvent to give Ru-terminated BPs “**BP-Ru**”. The reactions were quenched by the addition of **1** (5 equiv.) and stirring for another 2 h at RT. Size exclusion chromatography (SEC) analysis of the crude reaction revealed a highly efficient polymerization, with nearly quantitative conversion of PEG-MM to a unimodal peak corresponding to putative **BP-NHBoc** (M_n , SEC = 64 kDa, $D = 1.04$) (Fig. 2b). **BP-NHBoc** was purified by precipitation in cold diethyl ether to remove excess enyne terminator. The ^1H NMR spectrum for **BP-NHBoc** showed a unique resonance for the Boc end group (Fig. 2c and Fig. S1a, ESI†); the ratio of the integral of the backbone olefinic resonances to the Boc resonance was 40:9, which is consistent with the theoretical backbone degree of polymerization of 20. Together, these results suggest that **1** is an effective terminator for ROMP of PEGylated BPs.

Next, we sought to further modify the end of **BP-NHBoc** for bioconjugation using Pd(II) OACs. Exposure to trifluoroacetic acid gave complete conversion to the resulting amine-terminated BP **BP-NH2** (Fig. S1b, ESI†). Then, mixing with NHS ester **2** (Fig. 2a)^{8b} in phosphate buffer (pH = 8.5) for 12 h gave BP-OAC “**BP-Pd**”. Inductively coupled plasma-mass spectrometry (ICP-MS) was consistent with nearly quantitative introduction of Pd onto the chain ends (calculated 1000 ppb versus observed 1086 ppb) (Fig. S2, ESI†), with each BP-Pd having one Pd atom. ^1H NMR spectroscopy further showed the presence of resonances associated with the OAC (Fig. S3, ESI†), while the size of the BP was conserved as indicated by SEC (Fig. 2b).

With **BP-Pd** in hand, we explored bioconjugation using BSA (583 amino acids; 66.5 kDa) as a model protein as it contains a single free cysteine available for site-specific conjugation.¹⁰ BSA and **BP-Pd** were combined either in pure water or in phosphate-buffered saline (PBS) (pH = 7.4). Analysis of the crude reaction by SDS-PAGE gel electrophoresis (Fig. 3a and Fig. S4, ESI†) showed a new smear band with a significantly higher molecular weight (~180 kDa) compared to BSA alone, suggesting the successful formation of conjugate “**BP-BSA**”. The band at ~120 kDa for the crude conjugate (Fig. 3a and Fig. S4, ESI†) is assigned to the dimer of BSA. While separation of **BP-BSA** from free BSA and **BP-Pd** was difficult using preparatory SEC due to the similar hydrodynamic sizes of each component (Fig. S5, ESI†), anion exchange fast protein liquid chromatography (FPLC) using pH 8.5 buffer (in which BSA is negatively charged; pI = 4.7) enabled facile purification of the conjugates (Fig. 3b) as confirmed by SDS PAGE gel electrophoresis (Fig. 3a). The circular dichroism (CD) spectrum of purified **BP-BSA** (Fig. 3c) was nearly identical to that of the crude conjugation reaction mixture and BSA alone, suggesting that BSA maintains its folded structure following conjugation and purification.

FRET experiments using cyanine 3 (Cy3, $\lambda_{\text{ex}} = 555$ nm, $\lambda_{\text{em}} = 569$ nm) and cyanine 5 (Cy5, $\lambda_{\text{ex}} = 651$ nm, $\lambda_{\text{em}} = 670$ nm) dyes was designed to provide further evidence for the successful




Fig. 3 **BP-BSA** synthesis, purification, and characterization. (a) SDS PAGE Gel showing BSA, **BP-Pd**, crude **BP-BSA**, and purified **BP-BSA**. (b) FPLC trace for crude **BP-BSA**. (c) CD spectra for **BP-Pd**, BSA, crude **BP-BSA**, and purified **BP-BSA**.

conjugation of BPs to BSA. First, a Cy3-labeled BP “**BP^{Cy3}-Pd**” was synthesized following the same general procedure used for the synthesis of **BP-Pd** but using a mixture of PEG-MM and 5% of a Cy3-labeled PEG MM (Fig. S6 and S7, ESI†). Meanwhile, Cy5-labeled BSA “**BSA^{Cy5}**” was prepared through lysine conjugation using a commercially available Cy-5 NHS ester. Mixing **BP^{Cy3}-Pd** and **BSA^{Cy5}** gave conjugate **BP^{Cy3}-BSA^{Cy5}** via cysteine arylation. A control conjugate **BP^{Cy3}-BSA** was also prepared using unlabeled BSA. Both conjugates were purified by FPLC as described for **BP-BSA** (Fig. S8, ESI†). SDS-PAGE gel electrophoresis was used to characterize the proposed conjugates. As expected, **BP^{Cy3}-BSA^{Cy5}** showed strong signals in both the Cy3 and Cy5 channels, while **BP^{Cy3}-BSA** and **BSA^{Cy5}** only showed bands in the Cy3 and Cy5 channels, respectively (Fig. 4a). UV-vis spectroscopy supported these findings; the conjugate **BP^{Cy3}-BSA^{Cy5}** displayed absorption peaks that overlap with **BP^{Cy3}-Pd** and **BSA^{Cy5}** (Fig. 4b). Fluorescence emission spectra ($\lambda_{\text{ex}} = 550$ nm; Cy3 absorption) were collected for **BP^{Cy3}**, **BSA^{Cy5}**, a physical mixture of **BP^{Cy3}** and **BSA^{Cy5}**, and FPLC-purified **BP^{Cy3}-BSA^{Cy5}**. In support of the proposed conjugate structure, FRET-induced Cy5 emission ($\lambda_{\text{em}} = 670$ nm) was only observed for the conjugate **BP^{Cy3}-BSA^{Cy5}** (Fig. 4c).

Next, we evaluated the stability of **BP-BSA**, which features aryl thioether linkages, compared to analogous conjugates prepared using the cysteine-maleimide conjugation reaction (**BP-BSA-Mal**). Maleimide-terminated BP “**BP-Mal**” was prepared from **BP-NH2** and a commercially available NHS-ester maleimide under similar conditions as were used for the synthesis of **BP-Pd** from **BP-NH2** and **2** (Fig. S9, ESI†), demonstrating generality of our BP end-functionalization strategy. Conjugation of **BP-Mal** to BSA was conducted following commonly reported conditions (in PBS, 24 h). Notably, the conjugation conversion was much lower than for the Pd-mediated arylation reaction, as determined by FPLC (Fig. 3b and Fig. S9c, ESI†). Nevertheless, conjugate **BP-BSA-Mal** could be






Fig. 4 Dye-functionalized BP-BSA conjugates for FRET experiments. (a) Fluorescence gel images under Cy3/Cy5 channels. (b) UV-vis absorbance of BSA^{Cy5}, BP^{Cy3}-Pd, and BP^{Cy3}-BSA^{Cy5} conjugates. (c) Fluorescence emission spectra for BP^{Cy3}-Pd, BSA^{Cy5}, a physical mixture of BP^{Cy3}-Pd and BSA^{Cy5}, and BP^{Cy3}-BSA^{Cy5} ($\lambda_{\text{ex}} = 550$ nm).

isolated following FPLC purification (Fig. S10, ESI[†]). Exposing BP-BSA and BP-BSA-Mal to glutathione (~1000 equiv.; 10 mM), which is present in mM concentrations in the cytosol and is known to induce thiolate exchange with thiosuccinimides,¹¹ induced no changes for BP-BSA but led to the emergence of a new SDS-PAGE gel band consistent with free BSA for BP-BSA-Mal. Together, these findings support the successful conjugation of BP and BSA using either Pd(II)-induced cysteine arylation or maleimide conjugation, with the former displaying improved stability toward glutathione.

Finally, to demonstrate the generality of this approach, we formed conjugates between BP-Pd and a chemically synthesized protein, ERG,¹² (94 amino acids; ~11 kDa; Fig. S11a, ESI[†]) containing a single cysteine residue. Conjugation following the same general procedure used for BSA followed by FPLC purification gave "BP-ERG" in high conversion as indicated by FPLC (Fig. S11b, ESI[†]) and SDS-PAGE gel electrophoresis (Fig. S11c, ESI[†]).

In conclusion, we report a strategy to conjugate BPs directly to proteins. Our approach leverages ROMP for BP synthesis and achieves efficient conjugation to cysteine residues of proteins *via* an "organometallic swap" of Ru to Pd made possible by an enyne ROMP terminator. This approach allows for the merger of two independent methods that are each powerful for the applications in which they were developed (*e.g.*, ROMP for BP synthesis and Pd-mediated cysteine arylation for bioconjugation) but are traditionally orthogonal. The result is a new class of BP-protein conjugates with numerous potential applications that could leverage the utility of BPs for drug delivery and imaging¹³ with the therapeutic and targeting potential of proteins.

We thank the National Institutes of Health (2R01CA220468-06A1) for support. B. L. thanks the Ludwig Center of the Koch

Institute for Integrative Cancer Research at MIT for a postdoctoral fellowship. We thank S. L. Buchwald for helpful discussions.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- (a) C. Chen, D. Y. W. Ng and T. Weil, *Prog. Polym. Sci.*, 2020, **105**, 101241; (b) H. G. Börner, *Prog. Polym. Sci.*, 2009, **34**, 811–851; (c) A. S. Hoffman and P. S. Stayton, *Prog. Polym. Sci.*, 2007, **32**, 922; (d) Y. Qi and A. Chilkoti, *Curr. Opin. Chem. Biol.*, 2015, **28**, 181; (e) I. Cobo, M. Li, B. S. Sumerlin and S. Perrier, *Nat. Mater.*, 2015, **14**, 143; (f) T. A. Wright, R. C. Page and D. Konkolewicz, *Polym. Chem.*, 2019, **10**, 434; (g) M. Takahara, R. Wakabayashi, K. Minamihata, M. Goto and N. Kamiya, *Bioconjugate Chem.*, 2017, **28**, 2954; (h) M. A. Gauthier and H. A. Klok, *Chem. Commun.*, 2008, 2591; (i) K. Fuhrmann and G. Fuhrmann, *Curr. Opin. Colloid Interface Sci.*, 2017, **31**, 67; (j) X. Liu and W. Gao, *Angew. Chem., Int. Ed.*, 2021, **60**, 11024; (k) R. Duncan, *Nat. Rev. Cancer*, 2006, **6**, 688.
- (a) C. J. White and J. W. Bode, *ACS Cent. Sci.*, 2018, **4**, 197; (b) V. Gupta, S. Bhavanasi, M. Quadir, K. Singh, G. Ghosh, K. Vasamreddy, A. Ghosh, T. J. Siahann, S. Banerjee and S. K. Banerjee, *J. Cell Commun. Signal.*, 2019, **13**, 319; (c) Y. Hou and H. Lu, *Bioconjugate Chem.*, 2019, **30**, 1604; (d) J. M. Harris and R. B. Chess, *Nat. Rev. Drug Discovery*, 2003, **2**, 214; (e) M. Hamidi, A. Azadi and P. Rafiei, *Drug Delivery*, 2006, **13**, 399; (f) J. Herzberger, K. Niederer, H. Pohlitz, J. Seiwert, M. Worm, F. R. Wurm and H. Frey, *Chem. Rev.*, 2016, **116**, 2170; (g) M. J. Guicharda, T. Lealb and R. Vanbever, *Curr. Opin. Colloid Interface Sci.*, 2017, **31**, 43; (h) <https://www.biochempeg.com/article/58.html>.
- (a) N. Nischan and C. P. R. Hackenberger, *J. Org. Chem.*, 2014, **79**, 10727; (b) P. B. Lawrence, W. M. Billings, M. B. Miller, B. K. Pandey, A. R. Stephens, M. I. Langlois and J. L. Price, *ACS Chem. Biol.*, 2016, **11**, 1805; (c) J. Morgenstern, P. Baumann and C. Brunner, *Int. J. Pharm.*, 2017, **519**, 408.
- (a) C. Pinholt, J. T. Bukrinsky, S. Hostrup, S. Frokjaer, W. Norde and L. Jorgensen, *Eur. J. Pharm. Biopharm.*, 2011, **77**, 139; (b) J. Ramon, V. Saez, R. Baez, R. Aldana and E. Hardy, *Pharm. Res.*, 2005, **22**, 1374; (c) W. Lee, E. J. Park, S. Kwak, K. C. Lee, D. H. Na and J. S. Bae, *Biomacromolecules*, 2016, **17**, 1160.
- (a) W. Gao, W. Liu, J. A. Mackay, M. R. Zalutsky, E. J. Toone and A. Chilkoti, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 15231; (b) Y. Qi, A. Simakova, N. J. Ganson, X. Li, K. M. Luginbuhl, I. Ozer, W. Liu, M. S. Hershenfeld, K. Matyjaszewski and A. Chilkoti, *Nat. Biomed. Eng.*, 2016, **1**, 0002; (c) P. C. Nauka, J. Lee and H. D. Maynard, *Polym. Chem.*, 2016, **7**, 2352.
- (a) O. M. Ogba, N. C. Warner, D. J. O'Leary and R. H. Grubbs, *Chem. Soc. Rev.*, 2018, **47**, 4510; (b) J. Liu, A. O. Burts, Y. Li, A. V. Zhukhovitskiy, M. F. Ottaviani, N. J. Turro and J. A. Johnson, *J. Am. Chem. Soc.*, 2012, **134**, 16337.
- (a) E. Baslé, N. Joubert and M. Pucheault, *Chem. Biol.*, 2010, **17**, 213; (b) O. Boutoureira and G. J. L. Bernardes, *Chem. Rev.*, 2015, **115**, 2174.
- (a) E. V. Vinogradova, C. Zhang, A. M. Spokoiny, B. L. Pentelute and S. L. Buchwald, *Nature*, 2015, **526**, 687; (b) H. H. Dhanjee, I. Buslov, I. W. Windsor, R. T. Raines, B. L. Pentelute and S. L. Buchwald, *J. Am. Chem. Soc.*, 2020, **142**, 21237; (c) M. Jbara, J. Rodriguez, H. H. Dhanjee, A. Loas, S. L. Buchwald and B. L. Pentelute, *Angew. Chem., Int. Ed.*, 2021, **60**, 12109.
- (a) T. Zhang, L. Fu and W. R. Gutekunst, *Macromolecules*, 2018, **51**, 6497; (b) L. Fu, T. Zhang, G. Fu and W. R. Gutekunst, *J. Am. Chem. Soc.*, 2018, **140**, 12181.
- J. G. Mehtala, C. Kulczar, M. Lavan, G. Knipp and A. Wei, *Bioconjugate Chem.*, 2015, **26**, 941.
- A. D. Baldwin and K. L. Kiick, *Bioconjugate Chem.*, 2011, **22**, 1946.
- A. J. Callahan, S. Gandhesiri, T. L. Travaline, R. M. Reja, L. L. Salazar, S. Hanna, Y.-C. Lee, K. Li, O. S. Tokareva, J. M. Swiecicki, A. Loas, G. L. Verdine, J. H. McGee and B. L. Pentelute, *Nat. Commun.*, 2024, **15**, 1813.
- M. Müllner, *Chem. Commun.*, 2022, **58**, 5683.

